NEONATAL LUPUS SYNDROME – AN OVERVIEW OF THE PATHOGENESIS, CLINICAL FEATURES, AND MANAGEMENT APPROACH
Keywords:
neonatal lupus erythematosus, congenital heart block, cutaneous lupus syndrome, antibodies, autoimmune diseaseAbstract
Neonatal lupus erythematosus (NLE) is a rare immune-mediated condition that affects newborns due to the transplacental transfer of maternal antibodies, specifically anti-Ro/SSA and/or anti-La/SSB. Seropositive mothers may have known or undiagnosed autoimmune diseases, and many of them remain asymptomatic.
NLE is associated with various phenotypic characteristics and can affect multiple organ systems, including the skin, heart, blood, and liver. The most severe manifestation of NLE is a complete atrioventricular block, which may occur in utero and is irreversible. Cutaneous manifestations resemble the rash seen in subacute lupus erythematosus and are generally benign and self-limiting, typically resolving completely within four to six months.
During the neonatal period, these rashes are frequently misdiagnosed and confused with other common erythematous conditions, particularly when the mother is asymptomatic.
Although NLE typically has a benign course, its clinical significance is highlighted by a tenfold increased risk of recurrence in subsequent pregnancies, as well as its association with more severe clinical outcomes. This article provides a comprehensive review of pathogenesis, clinical manifestations and management of NLE aiming to serve as a valuable reference for clinical practitioners in the field.
References
Buyon JP, Clancy RM. Neonatal lupus syndromes. Curr Opin Rheumatol. 2003 Sep;15(5):535-41. doi: 10.1097/00002281-200309000-00003.
Vanoni F, Lava SAG, Fossali EF, Cavalli R, Simonetti GD, Bianchetti MG, Bozzini MA, Agostoni C, Milani GP. Neonatal Systemic Lupus Erythematosus Syndrome: a Comprehensive Review. Clin Rev Allergy Immunol. 2017; 53(3):469-476. doi: 10.1007/s12016-017-8653-0.
Izmirly PM, Halushka MK, Rosenberg AZ, Whelton S, Rais-Bahrami K, Nath DS, et al. Clinical and pathologic implications of extending the spectrum of maternal autoantibodies reactive with ribonucleoproteins associated with cutaneous and now cardiac neonatal lupus from SSA/Ro and SSB/La to U1RNP. Autoimmun Rev. 2017;16(9):980-3. doi:10.1016/j.autrev.2017.06.008.
Tran HB, Macardle PJ, Hiscock J, Cavill D, Bradley J, et al. Anti-La/SSB antibodies transported across the placenta bind apoptotic cells in fetal organs targeted in neonatal lupus. Arthritis Rheum. 2002;46(6):1572-9. doi:10.1002/art.10325.
Wisuthsarewong W, Soongswang J, Chantor R. Neonatal lupus erythematosus: clinical character, investigation, and outcome. Pediatr Dermatol. 2011;28(2):115–21. doi:10.1111/j.1525-1470.2010.01300.x.
Rivera TL, Izmirly PM, Birnbaum BK, et al. Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus. Ann Rheum Dis. 2009;68(5):828. doi:10.1136/ard.2008.092822.
Fritzler MJ, Pauls JD, Kinsella TD, Bowen TJ. Antinuclear, anticytoplasmic, and anti-Sjogren's syndrome antigen A (SS-A/Ro) antibodies in female blood donors. Clin Immunol Immunopathol. 1985;36(1):120. doi:10.1016/0090-1229(85)90027-6.
Satoh M, Chan EK, Ho LA, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 2012;64(7):2319-27. doi:10.1002/art.34490.
Keogan M, Kearns G, Jefferies CA. Extractable nuclear antigens and SLE: specificity and role in disease pathogenesis. In: Lahita RG, Tsokos G, Buyon J, Koike T, editors. Systemic Lupus Erythematosus, 5th ed. San Diego: Academic Press; 2011. p. 259.
Buyon JP, Clancy RM, Friedman DM. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nat Clin Pract Rheumatol. 2009;5(3):139-48. doi:10.1038/ncprheum0999.
Izmirly PM, Buyon JP, Saxena A. Neonatal lupus: advances in understanding pathogenesis and identifying cardiac disease treatments. Curr Opin Rheumatol. 2012;24(5):466-72. doi:10.1097/BOR.0b013e328356a343.
Derdulska JM, Rudnicka L, Szykut-Badaczewska A, et al. Neonatal lupus erythematosus - practical guidelines. J Perinat Med. 2021;49(5):529-38. doi:10.1515/jpm-2020-0441.
Teixeira V, Gonçalo M. Neonatal lupus erythematosus – review of pathophysiology and clinical implications. Acta Reumatol Port. 2012;37(4):314-23.
Cimaz R, Spence DL, Hornberger L, Silverman ED. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr. 2003;142(5):678-83. doi:10.1067/mpd.2003.157.
Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM, et al. Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum. 2004;50(10):3187-94. doi:10.1002/art.20513.
Izmirly PM, Saxena A, Kim MY, Wang D, Sahl SK, Llanos C, et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation. 2011;124(18):1927-35. doi:10.1161/CIRCULATIONAHA.111.044807.
Buyon JP, Winchester RJ, Slade SG, et al. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies. Arthritis Rheum. 1993;36(9):1263-71. doi:10.1002/art.1780360907.
Gordon P, Khamashta MA, Rosenthal E, et al. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol. 2004;31(12):2480-4.
Jaeggi E, Laskin C, Hamilton R, et al. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus: a prospective study of 186 antibody-exposed fetuses and infants. J Am Coll Cardiol. 2010;55(25):2778-84. doi:10.1016/j.jacc.2010.02.044.
Sheng X, Song X, Xiong Y, Ren T, Chang X, Wu J, et al. Maternal and infant outcomes of pregnancy associated with anti-SSA/RO antibodies: a systematic review and meta-analysis. Pediatr Rheumatol Online J. 2023;21(1):22. doi:10.1186/s12969-023-00803-0.
Sheth AP, Esterly NB, Ratoosh SL, Smith JP, Hebert AA, Silverman E. U1RNP positive neonatal lupus erythematosus: association with anti-La antibodies? Br J Dermatol. 1995;132(4):520-6. doi:10.1111/j.1365-2133.1995.tb08705.x.
Dugan EM, Tunnessen WW, Honig PJ, Watson RM. U1RNP antibody-positive neonatal lupus. A report of two cases with immunogenetic studies. Arch Dermatol. 1992;128(11):1490-4. doi:10.1001/archderm.1992.01680230082020.
Sirén MK, Julkunen H, Kaaja R, et al. Role of HLA in congenital heart block: susceptibility alleles in children. Lupus. 1999;8(1):60-5. doi:10.1191/096120399678901412.
Stevens AM, Hermes HM, Lambert NC, Nelson JL, Meroni PL, Cimaz R. Maternal and sibling microchimerism in twins and triplets discordant for neonatal lupus syndrome-congenital heart block. Rheumatology (Oxford). 2005;44(2):187-91. doi:10.1093/rheumatology/keh453.
Sonesson SE, Ambrosi A, Wahren-Herlenius M. Benefits of fetal echocardiographic surveillance in pregnancies at risk of congenital heart block: single-center study of 212 anti-Ro52-positive pregnancies. Ultrasound Obstet Gynecol. 2019;54(1):87-95. doi:10.1002/uog.19149.
Levesque K, Morel N, Maltret A, Baron G, Masseau A, Orquevaux P, et al. Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome. Autoimmun Rev. 2015;14(12):1154-60. doi:10.1016/j.autrev.2015.09.006.
Ho A, Gordon P, Rosenthal E, Simpson J, Miller O, Sharland G. Isolated complete heart block in the fetus. Am J Cardiol. 2015;116(1):142-7. doi:10.1016/j.amjcard.2015.04.053.
Neiman A, Lee L, Weston W, Buyon J. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. J Pediatr. 2000;137(5):674-80. doi:10.1067/mpd.2000.106677.
Savino F, Viola S, Tarasco V, Locatelli E, Ricagni A, Coppo P. Neonatal lupus erythematosus: a cutaneous cases based update. Ital J Pediatr. 2016;42:1. doi:10.1186/s13052-016-0227-4.
Penate Y, Guillermo N, Rodríguez J, Hernández-Machín B, Montenegro T, et al. Histopathologic characteristics of neonatal cutaneous lupus erythematosus: description of five cases and literature review. J Cutan Pathol. 2009;36(7):660-7. doi:10.1111/j.1600-0560.2009.01217.x.
Levy R, Briggs L, Silverman E, Pope E, Lara-Corrales I. Cutaneous sequelae in neonatal lupus: a retrospective cohort study. J Am Acad Dermatol. 2020;83(2):440-6. doi:10.1016/j.jaad.2019.11.033.
Palit A, Inamadar AC. Annular, erythematous skin lesions in a neonate. Indian Dermatol Online J. 2012;3(1):45-7. doi:10.4103/2229-5178.93504.
Saha A, Seth J, Mukherjee S, Basu S. Annular erythema of infancy: a diagnostic challenge. Indian J Pediatr Dermatol. 2014;15:147.
Lee LA, Sokol RJ, Buyon JP. Hepatobiliary disease in neonatal lupus: prevalence and clinical characteristics in cases enrolled in a national registry. Pediatrics. 2002;109(1):e11. doi:10.1542/peds.109.1.e11.
Laxer RM, Roberts EA, Gross KR, et al. Liver disease in neonatal lupus erythematosus. J Pediatr. 1990;116(2):238–42. doi:10.1016/s0022-3476(05)82880-x.
Hon KL, Leung AK. Neonatal lupus erythematosus. Autoimmune Dis. 2012;2012:301274. doi:10.1155/2012/301274.
Khayat AA, Alkhaldi AJ. Neonatal lupus presenting with neonatal hemochromatosis-like liver disease that responded to steroids: a case report. BMC Pediatr. 2022;22(1):630. doi:10.1186/s12887-022-03682-x.
Kim KR, Yoon TY. A case of neonatal lupus erythematosus showing transient anemia and hepatitis. Ann Dermatol. 2009;21(3):315.
Kanagasegar S, Cimaz R, Kurien BT, et al. Neonatal lupus manifests as isolated neutropenia and mildly abnormal liver functions. J Rheumatol. 2002;29(1):187.
Wolach B, Choc L, Pomeranz A, et al. Aplastic anemia in neonatal lupus erythematosus. Am J Dis Child. 1993;147(8):941.
Pereira S, Flor-de-Lima F, Soares H, et al. Pulmonary involvement in neonatal lupus: a challenging diagnosis - case report and literature review. Acta Reumatol Port. 2018;43(3):230-4.
Maltret A, Morel N, Levy M, et al. Pulmonary hypertension associated with congenital heart block and neonatal lupus syndrome: A series of four cases. Lupus. 2021;30(2):307-14. doi:10.1177/0961203320973073.
Boros CA, Spence D, Blaser S, Silverman ED. Hydrocephalus and macrocephaly: new manifestations of neonatal lupus erythematosus. Arthritis Rheum. 1996;39(9):1594-6. doi:10.1002/art.1780390921.
Chen CC, Lin KL, Chen CL, et al. Central nervous system manifestations of neonatal lupus: a systematic review. Lupus. 2013; 22:1484.
Cabañas F, Pellicer A, Valverde E, Morales C, Quero J. Central nervous system vasculopathy in neonatal lupus erythematosus. Pediatr Neurol. 1996 Sep;15(2):124-6. doi: 10.1016/0887-8994(96)00159-2.
Saini AG, Sankhyan N, Bhattad S, Vyas S, Saikia B, Singhi P. CNS vasculitis and stroke in neonatal lupus erythematosus: a case report and review of literature. Eur J Paediatr Neurol. 2014 May;18(3):444-8. doi: 10.1016/j.ejpn.2014.01.007.
Clowse MEB, Eudy AM, Kiernan E, et al. The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices. Rheumatology. 2018; 57: v9–v17.
Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126: 76–82.
Beksac MS, Donmez HG. Impact of hydroxychloroquine on the gestational outcomes of pregnant women with immune system problems that necessitate the use of the drug. J Obstet Gynaecol Res 2021; 47: 570–575.
Donofrio MT, Moon-Grady AJ, Hornberger LK, et al.; American Heart Association Adults With Congenital Heart Disease Joint Committee of the Council on Cardiovascular Disease in the Young and Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Council on Cardiovascular and Stroke Nursing. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation. 2014 May 27;129(21):2183-242. doi: 10.1161/01.cir.0000437597.44550.5d.
Saxena A, Izmirly PM, Mendez B, Buyon JP, Friedman DM. Prevention and treatment in utero of autoimmune-associated congenital heart block. Cardiol Rev. 2014 Nov-Dec;22(6):263-7. doi: 10.1097/CRD.0000000000000026.
Brucato A, Ramoni V, Gerosa M, Pisoni MP. Congenital fetal heart block: a potential therapeutic role for intravenous immunoglobulin. Author reply Obstet Gynecol. 2011;117:177. doi: 10.1097/AOG.0b013e3182042972.
Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Ann Rheum Dis 2020; 79: 3–18.
Zuppa AA, Riccardi R, Frezza S, Gallini F, Luciano RM, Alighieri G, Romagnoli C, De Carolis S. Neonatal lupus: Follow-up in infants with anti-SSA/Ro antibodies and review of the literature. Autoimmun Rev. 2017 Apr;16(4):427-432. doi: 10.1016/j.autrev.2017.02.010.
Martin V, Lee LA, Askanase AD, Katholi M, Buyon JP. Long-term followup of children with neonatal lupus and their unaffected siblings. Arthritis Rheum. 2002 Sep;46(9):2377-83. doi: 10.1002/art.10638.
